400 related articles for article (PubMed ID: 11336566)
21. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
Laine L
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
[TBL] [Abstract][Full Text] [Related]
22. Motion--Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments against the motion.
Maetzel A
Can J Gastroenterol; 2003 May; 17(5):335-8. PubMed ID: 12772009
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing.
Jones MK; Wang H; Peskar BM; Levin E; Itani RM; Sarfeh IJ; Tarnawski AS
Nat Med; 1999 Dec; 5(12):1418-23. PubMed ID: 10581086
[TBL] [Abstract][Full Text] [Related]
24. Epidemiology of NSAID-related gastroduodenal mucosal injury.
Aalykke C; Lauritsen K
Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):705-22. PubMed ID: 11566036
[TBL] [Abstract][Full Text] [Related]
25. Gastrointestinal safety of selective COX-2 inhibitors.
Hawkey CJ; Skelly MM
Curr Pharm Des; 2002; 8(12):1077-89. PubMed ID: 11945152
[TBL] [Abstract][Full Text] [Related]
26. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.
Meyer-Kirchrath J; Schrör K
Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962
[TBL] [Abstract][Full Text] [Related]
27. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.
Hawkey CJ; Langman MJ
Gut; 2003 Apr; 52(4):600-8. PubMed ID: 12631678
[TBL] [Abstract][Full Text] [Related]
28. Impact of COX-2 inhibitors in common clinical practice a gastroenterologist's perspective.
Lehmann FS; Beglinger C
Curr Top Med Chem; 2005; 5(5):449-64. PubMed ID: 15974940
[TBL] [Abstract][Full Text] [Related]
29. Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications.
Peura DA
Am J Med; 2004 Sep; 117 Suppl 5A():63S-71S. PubMed ID: 15478855
[TBL] [Abstract][Full Text] [Related]
30. The multisystem adverse effects of NSAID therapy.
James DS
J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S1-7. PubMed ID: 10643174
[TBL] [Abstract][Full Text] [Related]
31. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy].
Lanas A
Rev Gastroenterol Mex; 2004; 69(4):251-60. PubMed ID: 15765979
[TBL] [Abstract][Full Text] [Related]
32. [In vivo selectivity of nonsteroidal anti-inflammatory drugs on COX-1-COX-2 and gastrointestinal ulcers, in rats].
Laudanno OM; Cesolari JA; Esnarriaga J; Flaherty P; Vada J; Guastalli G; San Miguel P; Bedini OA
Acta Gastroenterol Latinoam; 1998; 28(3):249-55. PubMed ID: 9773153
[TBL] [Abstract][Full Text] [Related]
33. Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs.
Akarca US
Curr Pharm Des; 2005; 11(14):1779-93. PubMed ID: 15892675
[TBL] [Abstract][Full Text] [Related]
34. [Guidelines of prevention and treatment for NSAID-related peptic ulcers].
Lee JH; Lee YC; Jeon SW; Kim JW; Lee SW; ;
Korean J Gastroenterol; 2009 Nov; 54(5):309-17. PubMed ID: 19934612
[TBL] [Abstract][Full Text] [Related]
35. Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs.
Graham DY
Am J Med; 2001 Jan; 110(1A):58S-61S. PubMed ID: 11166000
[TBL] [Abstract][Full Text] [Related]
36. COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?
Cryer B
Gastroenterology; 2004 Oct; 127(4):1256-8. PubMed ID: 15481002
[No Abstract] [Full Text] [Related]
37. Challenges in managing NSAID-associated gastrointestinal tract injury.
Goldstein JL
Digestion; 2004; 69 Suppl 1():25-33. PubMed ID: 15001832
[TBL] [Abstract][Full Text] [Related]
38. Cyclo-oxygenase-1/cyclo-oxygenase-2 non selective non-steroidal anti-inflammatory drugs: epidemiology of gastrointestinal events.
Lanas A
Dig Liver Dis; 2001 Dec; 33 Suppl 2():S29-34. PubMed ID: 11827360
[TBL] [Abstract][Full Text] [Related]
39. "Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs.
Bennett K; Teeling M; Feely J
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):645-9. PubMed ID: 12942226
[TBL] [Abstract][Full Text] [Related]
40. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.
Hooper L; Brown TJ; Elliott R; Payne K; Roberts C; Symmons D
BMJ; 2004 Oct; 329(7472):948. PubMed ID: 15475342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
